It can be perfectly comprehended that IL-two is often a pleiotropic cytokine positioned in the crossroads of T cell activation and regulation. As a result, it can be critical to engineer an IL-two molecule that is certainly biased in direction of effector cells bearing the intermediate affinity receptor, including naïve and memory CD8+ T cells and